Sarepta Therapeutics, Inc. Quarterly Costs and Expenses in USD from Q1 2015 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
Sarepta Therapeutics, Inc. quarterly/annual Costs and Expenses history and growth rate from Q1 2015 to Q3 2024.
  • Sarepta Therapeutics, Inc. Costs and Expenses for the quarter ending September 30, 2024 was $445M, a 26.2% increase year-over-year.
  • Sarepta Therapeutics, Inc. Costs and Expenses for the twelve months ending September 30, 2024 was $1.56B, a 3.66% increase year-over-year.
  • Sarepta Therapeutics, Inc. annual Costs and Expenses for 2023 was $1.51B, a 2.86% increase from 2022.
  • Sarepta Therapeutics, Inc. annual Costs and Expenses for 2022 was $1.47B, a 26.5% increase from 2021.
  • Sarepta Therapeutics, Inc. annual Costs and Expenses for 2021 was $1.16B, a 5.19% increase from 2020.
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $1.56B $445M +$92.3M +26.2% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 $1.47B $364M -$31.1M -7.89% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $1.5B $379M -$13M -3.33% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-01
Q4 2023 $1.51B $372M +$6.9M +1.89% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 $1.5B $353M -$8.97M -2.48% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 $1.51B $395M -$49.9M -11.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 $1.56B $392M +$93.9M +31.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-01
Q4 2022 $1.47B $365M +$58M +18.9% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 $1.41B $362M +$138M +61.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-01
Q2 2022 $1.27B $445M +$113M +34.1% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $1.16B $298M -$1.09M -0.36% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-02
Q4 2021 $1.16B $307M -$8.58M -2.72% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 $1.17B $224M -$57.1M -20.3% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-02
Q2 2021 $1.23B $332M +$55.9M +20.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-02
Q1 2021 $1.17B $299M +$67.1M +29% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 $1.1B $316M -$14.5M -4.38% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-01
Q3 2020 $1.12B $281M +$58.4M +26.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 $1.06B $276M -$94.3M -25.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 $1.15B $232M +$68.3M +41.8% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 $1.09B $330M +$107M +47.6% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-01
Q3 2019 $980M $223M +$74M +49.8% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-01
Q2 2019 $906M $370M +$193M +109% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-01
Q1 2019 $713M $163M +$68.1M +71.4% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-01
Q4 2018 $645M $224M +$143M +178% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-26
Q3 2018 $501M $149M +$56.7M +61.8% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-26
Q2 2018 $445M $177M +$78.6M +79.9% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-26
Q1 2018 $366M $95.3M +$39.8M +71.5% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-26
Q4 2017 $326M $80.4M -$13.4M -14.3% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-28
Q3 2017 $340M $91.9M +$35.3M +62.5% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-28
Q2 2017 $304M $98.4M +$36.3M +58.4% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-28
Q1 2017 $268M $55.6M -$4.12M -6.89% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-28
Q4 2016 $272M $93.8M +$28.1M +42.8% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-01
Q3 2016 $244M $56.5M +$4.77M +9.22% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-01
Q2 2016 $239M $62.1M +$20M +47.5% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-01
Q1 2016 $219M $59.7M -$2.16M -3.49% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-01
Q4 2015 $221M $65.7M Oct 1, 2015 Dec 31, 2015 10-K 2017-02-28
Q3 2015 $51.8M Jul 1, 2015 Sep 30, 2015 10-K 2017-02-28
Q2 2015 $42.1M Apr 1, 2015 Jun 30, 2015 10-K 2017-02-28
Q1 2015 $61.9M Jan 1, 2015 Mar 31, 2015 10-K 2017-02-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.